MVS Solutions - The Technology Realization Company


Available for Licensing
Call 1.617.283.2182 or Email

Visit the MVS Solutions Technology Marketplace for Additional Licensing Opportunities


New Fusion Tag for Site-specific Conjugation of Payloads to Targeting Proteins

 

Description

Targeted delivery of therapeutic and diagnostic agents might significantly decrease systemic toxicity, increase efficacy of new and old drugs, support development of personalized medicine, and provide new uses for existing therapeutic proteins. Although many proteins can be used for targeted delivery, random conjugation of a "payload" to a protein creates heterogeneous products that are not well-suited for development and for regulatory approval. This invention eliminates random conjugation and provides a strategy for development of functionally active, homogeneous protein-based products. In this strategy, a protein is expressed with a humanized 15-aa cysteine-containing tag (Cys-tag), and a payload is site-specifically conjugated to a cysteine residue in Cys-tag via thiol-directed chemistries. Cys-tag is compatible with every protein tested so far, and accommodates payloads as different as drugs, contrast agents, dendrimers, liposomes, and functional proteins.

Benefits and Applications

  • Cys-tagged protein can be used for targeted delivery of therapeutic and diagnostic agents, dramatically expanding the field of use for a given protein therapeutic
  • Cys-tagged protein can be used in development of protein therapeutics to establish biodistribution and internalization
  • Cys-tagged protein can be modified to alter pharmacokinetic via site-specific pegylation
  • Cys-tagged protein can be modified to suit specific formulation, for example, slow-release formulations
  • Cys-tagged protein can be conjugated to tissue engineering scaffolds, biomedical surfaces, or nanoparticles, providing uniform protein-derivatized constructs

Intellectual Property Status

Patent Pending (US PTO #20050221431)

Related Publication

  • Mol. Cancer. Ther. 4, 1423-1429, 2005
  • Europ. J. Nucl. Med. Mol. Imag. 33, 841-848, 2006
  • Anti-Cancer Agents Med. Chem. 6, 167-184, 2006
  • Bioconjugate Chem., 17, 912-919, 2006
  • Biomaterials 27, 5452-5458, 2006

Interested parties call 1.617.283.2182 or Contact Us

 

Visit MVSSolutions.com for info about our technology development services. Visit MVSSolutions.biz for info about our enterprise development & business services. Visit MVSSolutions.us for info about our government contractor services. MVS Solutions - Conducting the Business of Technology (sm)

Conducting the Business of Science SM

HOME | WHO WE ARE | WHAT WE DO | AFFILIATIONS | CONTACT US | PRIVACY STATEMENT | JOBS | NEWS
CAPABILITIES | SITE MAP | COPYRIGHT AND TRADEMARK NOTICE | THE BUSINESS OF SCIENCE
TECHNICAL DUE DILIGENCE | REFERRALS - RECOMMENDATIONS | INTELLECTUAL PROPERTY
SITE SEARCH | WEB SEARCH | CONSULTANTS DIRECTORY | RESOURCES | EVENTS
INTERNATIONAL SITE | WIRELESS INTERNET SITE | MEDIA INFO
INDUSTRY NEWS FEEDS | CLIENT TESTIMONIALS
EXPERTISE | EXPERT WITNESS & CONSULTANT
EMERGING BUSINESS DEVELOPMENT
TECHNOLOGY COMMERCIALIZATION
COMPENSATION PHILOSOPHY
GREEN CHEMISTRY SUPPORT
BID - RFP - RFQ REQUESTS
COACHING & MENTORING
INDEPENDENT DIRECTOR
INVESTMENT BANKING
OUR MARKETS
OUR CLIENTS
MARKETING
US AGENT
IBEC

QUICK TOOLS


Resources:
Biotech | Chemistry | Medical Devices | Materials | Environmental | Engineering | Pharmaceutical | Green Chemistry | Technology Marketplace | Strategic Alliances & Partnering | Venture Capital & Funding | Grant Opportunities | Business | General | International | Search | Publications | Homeland Security | Web Directory | The Business of Science Newsletter


EMAIL

Deutsch | English | Español | Français | Italiano | Português




© 1999-2006 MVS Solutions Incorporated. All Rights Reserved.